Martinsried/ Munich, March 20, 2013. Medigene AG (Frankfurt, Prime Standard) and SynCore Biotechnology Co., Ltd. ("SynCore"), a member of the Sinphar Pharmaceutical Group, have expanded the existing exclusive licensing and supply contract into new regions for the supply and marketing of the Veregen® ointment for the treatment of genital warts. Along with existing agreements in Taiwan, SynCore will now be responsible for the approval process and commercialization of the drug for the treatment of genital warts throughout Asia* (excl. China and Korea), in Australia and New Zealand. In addition to income from the production and supply of the ointment and the active ingredient, Medigene will receive payment when specific milestones are reached. Medigene already has partnerships in Asia for the distribution of Veregen® in China (GC Rise Pharmaceutials) and South Korea (Kolon Pharmaceuticals).
Dr. Frank Mathias, CEO of Medigene AG comments: "We are delighted that we have intensified our partnership with SynCore further. Alongside the co-development and commercialization partnership for our drug candidate EndoTAG®-1 which was entered into last year, we have now also been able to significantly expand our collaboration for the marketing of Veregen®. Together with SynCore and our other Asian distribution partners, we will be able to tap into the markets with Veregen® in Asia and the key region of Oceania as quickly as possible."
Veregen® is already marketed in the USA (by Fougera), in Germany, Austria, Switzerland (by Abbott) and Spain (by Bial). Market authorization has been granted for other countries or is expected within the next few months. A number of partnerships are in place in Europe, Asia and America for the marketing of Veregen®. Medigene intends to conclude further marketing partnerships in additional countries to fully exploit the market potential of Veregen®.
* Afghanistan, Bangladesh, Bhutan, Brunei, Burma, Cambodia, Indonesia, Iran, Iraq, Japan, Laos, Maldives, Mongolia, Nepal, Pakistan, Philippines, Singapore, Sri Lanka, Thailand and Vietnam.
About Veregen®: Veregen®, an ointment used in the topical treatment of external genital warts, contains a catechin concentrate based on a defined extract obtained from green tea leaves. Since 2010, Veregen® (Sinecatechins 15% ointment) has been recommended in the US Department of Health and Human Services Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines as a possible option for treating genital warts. Sinecatechins 10% & 15% ointment (Veregen®) was recently also included in the European Guideline for the Management of Anogenital Warts.
About SynCore: SynCore Biotechnology Co., Ltd, a joint venture between Sinphar Pharmaceutical Co., Ltd and the National Health Research Institute Taiwan, focuses on the development and pipeline management of new drugs. Currently, SynCore has five products under development in different stages of clinical trial. Additionally, SynCore has been granted the exclusive development and marketing right in Asia for a new drug for the treatment of dry AMD (age-related macular degeneration) from MacuCLEAR, an US-based biotech company; the drug received approval to enter into phase II/III clinical trial in the US and Taiwan. For further information, please visit www.syncorebio.com.
About Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd (Taiwan Stock Exchange, Symbol: 1734), with subsidiaries in China and Canada, specializes in the sales and marketing of pharmaceutical products and dietary supplements as well as in manufacturing for several global pharma companies like Johnson & Johnson, Takeda, Shionogi and Astellas. Additionally, Sinphar is one of the largest producers of paclitaxel (Phyxol®) in Asia. It is also involved in the research and development of botanical new drugs. Further information can be obtained at www.sinphar.com.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.